Last reviewed · How we verify
CiVi007
At a glance
| Generic name | CiVi007 |
|---|---|
| Sponsor | Civi Biopharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy (PHASE2)
- A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CiVi007 CI brief — competitive landscape report
- CiVi007 updates RSS · CI watch RSS
- Civi Biopharma, Inc. portfolio CI